O	0	6	Effect
O	7	9	of
B-intervention	10	17	Dietary
I-intervention	18	26	Flaxseed
I-intervention	27	33	Intake
O	34	36	on
O	37	48	Circulating
O	49	52	Sex
O	53	60	Hormone
O	61	67	Levels
O	68	73	among
B-eligibility	74	88	Postmenopausal
I-eligibility	89	94	Women
O	94	95	:
O	96	97	A
O	98	108	Randomized
O	109	119	Controlled
O	120	132	Intervention
O	133	138	Trial
O	138	139	.

O	140	146	Lignan
O	147	153	intake
O	153	154	,
O	155	158	and
O	159	162	its
O	163	170	richest
O	171	175	food
O	176	182	source
O	182	183	,
O	184	192	flaxseed
O	192	193	,
O	194	198	have
O	199	203	been
O	204	214	associated
O	215	219	with
O	220	227	reduced
O	228	234	breast
O	235	241	cancer
O	242	246	risk
O	246	247	.

O	248	258	Endogenous
O	259	262	sex
O	263	271	hormones
O	271	272	,
O	273	277	such
O	278	280	as
O	281	290	estrogens
O	290	291	,
O	292	296	play
O	297	298	a
O	299	303	role
O	304	306	in
O	307	313	breast
O	314	320	cancer
O	321	332	development
O	332	333	,
O	334	337	and
O	338	345	lignans
O	346	349	may
O	350	355	alter
O	356	361	these
O	362	365	sex
O	366	373	hormone
O	374	380	levels
O	380	381	.

O	382	384	To
O	385	391	assess
O	392	395	the
O	396	402	effect
O	403	405	of
O	406	414	flaxseed
O	415	417	on
O	418	429	circulating
O	430	433	sex
O	434	442	hormones
O	442	443	,
O	444	445	a
O	446	456	randomized
O	457	467	controlled
O	468	473	trial
O	474	477	was
O	478	487	conducted
O	488	493	among
B-total-participants	494	496	99
B-eligibility	497	511	postmenopausal
I-eligibility	512	517	women
O	518	520	in
B-location	521	528	Toronto
I-location	528	529	,
I-location	530	536	Canada
O	536	537	.

O	538	541	The
O	542	554	intervention
O	555	558	arm
O	559	567	consumed
O	568	569	2
O	570	581	tablespoons
O	582	583	(
O	583	585	15
O	586	587	g
O	587	588	)
O	589	591	of
O	592	598	ground
O	599	607	flaxseed
O	608	613	daily
O	614	617	for
O	618	619	7
O	620	625	weeks
O	625	626	;
O	627	630	the
B-control	631	638	control
I-control	639	642	arm
O	643	653	maintained
O	654	659	usual
O	660	664	diet
O	664	665	.

O	666	674	Baseline
O	675	678	and
O	679	683	week
O	684	685	7
O	686	700	concentrations
O	701	703	of
O	704	706	14
O	707	712	serum
O	713	716	sex
O	717	725	hormones
O	726	730	were
O	731	739	measured
O	740	745	using
O	746	752	liquid
O	753	767	chromatography
O	767	768	-
O	768	774	tandem
O	775	779	mass
O	780	792	spectrometry
O	793	794	(
O	794	796	LC
O	796	797	-
O	797	799	MS
O	799	800	/
O	800	802	MS
O	802	803	)
O	804	807	and
O	808	819	immunoassay
O	819	820	,
O	821	824	and
O	825	830	serum
O	831	844	enterolignans
O	845	846	(
O	846	852	lignan
O	853	862	biomarker
O	862	863	)
O	864	869	using
O	870	872	LC
O	872	873	-
O	873	875	MS
O	875	876	/
O	876	878	MS
O	878	879	.

O	880	892	Intervention
O	893	900	effects
O	901	903	on
O	904	907	sex
O	908	915	hormone
O	916	922	levels
O	923	927	were
O	928	936	assessed
O	937	942	using
O	943	951	analysis
O	952	954	of
O	955	965	covariance
O	965	966	.

B-outcome	967	972	Serum
I-outcome	973	986	enterolignans
I-outcome	987	996	increased
O	997	1002	among
O	1003	1006	the
O	1007	1015	flaxseed
O	1016	1019	arm
O	1020	1021	(
O	1021	1022	+
O	1022	1025	516
O	1025	1026	%
O	1026	1027	)
O	1027	1028	.

O	1029	1034	Women
O	1035	1044	consuming
O	1045	1053	flaxseed
O	1054	1055	(
O	1055	1057	vs
O	1057	1058	.
O	1059	1067	controls
O	1067	1068	)
O	1069	1072	had
O	1073	1082	increased
B-outcome	1083	1088	serum
I-outcome	1089	1090	2
I-outcome	1090	1091	-
I-outcome	1091	1105	hydroxyestrone
O	1106	1107	[
O	1107	1116	treatment
O	1117	1123	effect
O	1124	1129	ratio
O	1130	1131	(
O	1131	1134	TER
O	1134	1135	)
O	1136	1137	=
O	1138	1139	1
O	1139	1140	.
O	1140	1142	54
O	1142	1143	;
O	1144	1146	95
O	1146	1147	%
O	1148	1150	CI
O	1150	1151	:
O	1152	1153	1
O	1153	1154	.
O	1154	1156	18
O	1156	1157	-
O	1157	1158	2
O	1158	1159	.
O	1159	1161	00
O	1161	1162	]
O	1163	1166	and
B-outcome	1167	1168	2
I-outcome	1168	1169	:
I-outcome	1169	1171	16
I-outcome	1171	1172	α
I-outcome	1172	1173	-
I-outcome	1173	1187	hydroxyestrone
I-outcome	1188	1193	ratio
O	1194	1195	(
O	1195	1198	TER
O	1199	1200	=
O	1200	1201	1
O	1201	1202	.
O	1202	1204	54
O	1204	1205	;
O	1206	1208	95
O	1208	1209	%
O	1210	1212	CI
O	1212	1213	:
O	1214	1215	1
O	1215	1216	.
O	1216	1218	15
O	1218	1219	-
O	1219	1220	2
O	1220	1221	.
O	1221	1223	06
O	1223	1224	)
O	1224	1225	;
O	1226	1233	effects
O	1234	1236	on
O	1237	1242	other
O	1243	1251	hormones
O	1252	1256	were
O	1257	1260	not
O	1261	1274	statistically
O	1275	1286	significant
O	1286	1287	.

O	1288	1294	Within
O	1295	1298	the
O	1299	1307	flaxseed
O	1308	1311	arm
O	1311	1312	,
B-outcome	1313	1319	change
I-outcome	1320	1322	in
I-outcome	1323	1335	enterolignan
I-outcome	1336	1341	level
O	1342	1345	was
O	1346	1356	positively
O	1357	1367	correlated
O	1368	1372	with
O	1373	1380	changes
O	1381	1383	in
O	1384	1385	2
O	1385	1386	-
O	1386	1400	hydroxyestrone
O	1401	1404	and
O	1405	1406	2
O	1406	1407	:
O	1407	1409	16
O	1409	1410	α
O	1410	1411	-
O	1411	1425	hydroxyestrone
O	1426	1431	ratio
O	1431	1432	,
O	1433	1436	and
O	1437	1447	negatively
O	1448	1452	with
O	1453	1462	prolactin
O	1462	1463	.

O	1464	1472	Findings
O	1473	1480	suggest
O	1481	1489	flaxseed
O	1490	1497	affects
O	1498	1505	certain
O	1506	1517	circulating
O	1518	1521	sex
O	1522	1529	hormone
O	1530	1536	levels
O	1537	1541	with
O	1542	1550	possible
O	1551	1563	implications
O	1564	1567	for
O	1568	1574	future
O	1575	1581	breast
O	1582	1588	cancer
O	1589	1599	prevention
O	1600	1608	research
O	1608	1609	.
